Flexion Therapeutics (Flexion Therapeutics) Operating Income : $-78.5 Mil (TTM As of Sep. 2021)

View and export this data going back to 2014. Start your Free Trial

What is Flexion Therapeutics Operating Income?

Flexion Therapeutics's Operating Income for the three months ended in Sep. 2021 was $-24.2 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2021 was $-78.5 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Flexion Therapeutics's Operating Income for the three months ended in Sep. 2021 was $-24.2 Mil. Flexion Therapeutics's Revenue for the three months ended in Sep. 2021 was $21.3 Mil. Therefore, Flexion Therapeutics's Operating Margin % for the quarter that ended in Sep. 2021 was -113.28%.

Flexion Therapeutics's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Flexion Therapeutics's annualized ROC % for the quarter that ended in Sep. 2021 was -180.79%. Flexion Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2021 was -260.45%.

Flexion Therapeutics Operating Income Historical Data

The historical data trend for Flexion Therapeutics's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flexion Therapeutics Operating Income Chart

Flexion Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Operating Income

Get a 7-Day Free Trial

-69.78

-129.68

-159.20

-136.27

-93.02

Flexion Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Operating Income	Get a 7-Day Free Trial															-18.87	-14.30	-23.14	-16.88	-24.16

Flexion Therapeutics Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.5 Mil.

Flexion Therapeutics (NAS:FLXN) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Flexion Therapeutics's annualized ROC % for the quarter that ended in Sep. 2021 is calculated as:

	ROC % (Q: Sep. 2021 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2021 )	+	Invested Capital (Q: Sep. 2021 ))	/ count )
=	-96.632 * ( 1 - 0% )	/	( (57.581	+	49.321)	/ 2 )
=	-96.632	/	53.451
=	-180.79 %

where

	Invested Capital		(Q: Jun. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	210.047	-	21.217	-	( 131.249	-	max(0, 39.931	-	184.121	+	131.249	))
=	57.581

	Invested Capital		(Q: Sep. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	217.931	-	26.557	-	( 142.053	-	max(0, 43.986	-	192.756	+	142.053	))
=	49.321

Note: The Operating Income data used here is four times the quarterly (Sep. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Flexion Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2021 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2021 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2021		Q: Sep. 2021
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-98.1	/	( ( (25.926 + max(15.912, 0))	+	(25.175 + max(8.318, 0)) )	/	2 )
=	-98.1	/	( ( 41.838	+	33.493 )	/	2 )
=	-98.1	/	37.6655
=	-260.45 %

where Working Capital is:

	Working Capital		(Q: Jun. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(35.097	+	12.301	+	5.34)	-	(21.217	+	10	+	5.609)
=	15.912

	Working Capital		(Q: Sep. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(29.375	+	14.669	+	6.641)	-	(26.557	+	10	+	5.81)
=	8.318

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2021) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Flexion Therapeutics's Operating Margin % for the quarter that ended in Sep. 2021 is calculated as:

Operating Margin %	=	Operating Income (Q: Sep. 2021 )	/	Revenue (Q: Sep. 2021 )
	=	-24.158	/	21.326
	=	-113.28 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Flexion Therapeutics Operating Income Related Terms

Thank you for viewing the detailed overview of Flexion Therapeutics's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Flexion Therapeutics (Flexion Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Flexion Therapeutics Inc (NAS:FLXN) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Mall Road, Suite 301, Burlington, MA, USA, 01803

Website

http://www.flexiontherapeutics.com

Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra-articular corticosteroid treatment.

Executives

Mark S. Levine	officer: General Counsel	1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Kerry Wentworth	officer: Chief Regulatory Officer	AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Christina Willwerth	officer: Chief Strategy Officer	C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803
David Arkowitz	officer: Chief Financial Officer	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Melissa Layman	officer: Chief Commercial Officer	C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, STE. 301 BURLINGTON MA 01803
Scott Kelley	officer: Chief Medical Officer	C/O ASPECT MEDICAL SYSTEMS INC 141 NEEDHAM ST NEWTON MA 02464-1505
Elizabeth Kwo	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael D. Clayman	director, officer: President and CEO	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Alan Milinazzo	director	C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078
Scott A Canute	director	FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
C Ann Merrifield	director
Heath Lukatch	director	326 BOLLAY DRIVE, GOLETA CA 93117
Samuel D Colella	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Patrick J Mahaffy	director	C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Mark Stejbach	director	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403